BTIG Downgrades Heartware Int'l (HTWR) to Neutral

Canaccord Genuity Remains Bullish on Heartware (HTWR) Following Agreement to Acquire Valtech Cardio

Canaccord Genuity maintained a Buy rating and $106.00 price target on Heartware Int'l (NASDAQ: HTWR) following the company's agreement to acquire privately held Valtech Cardio. Analyst Jason Mills said that this is the type of deal to which investors commonly overreact; but once the dust settles, he would be a buyer of this stock.

Mills commented, "HeartWares agreement to acquire... More

Heartware International's (HTWR) Valtech Cardio Acquisition Doesn't Make Sense, Says Northland

Northland Capital Markets maintained an Underperform rating on Heartware International (NASDAQ: HTWR) with a price target of $60. Analyst Suraj Kalia said the company's acquisition of Valtech Cardio does not makes sense.

Kalia explained, "Valtech is a pre-revenue company developing surgical & transcatheter mitral repair / replacement... More

Raymond James Downgrades Heartware (HTWR) to Market Perform

Raymond James downgraded Heartware Int'l (NASDAQ: HTWR) from Outperform to Market Perform and removed its price target (prior $102.00).

For an analyst ratings summary and ratings history on Heartware Int'l click here. For more ratings news on Heartware Int'l click here.

Shares of Heartware Int'l closed at $81.81 yesterday.

Heartware (HTWR) to Acquire Valtech Cardio

Heartware (NASDAQ: HTWR) announced today that it has entered into a definitive agreement to acquire Valtech Cardio, Ltd. ("Valtech"). Valtech is a privately held company that specializes in the development of innovative surgical and transcatheter valve repair and replacement devices for the treatment of the most prevalent heart valve diseases mitral valve regurgitation (MR) and... More